B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

SCN5A

MOLECULAR TARGET

sodium voltage-gated channel alpha subunit 5

UniProt: Q14524NCBI Gene: 633119 compounds

SCN5A (sodium voltage-gated channel alpha subunit 5) is targeted by 19 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting SCN5A

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Quinidine1.614
2Saxitoxin1.393
3Duloxetine Hydrochloride1.102
4Aconitine1.102
5Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent1.102
6Flecainide1.102
7Lidocaine1.102
8Nebivolol1.102
9Propranolol1.102
10Ranolazine1.102
11Astemizole Antihistamine drug now withdrawn from0.691
12Bupivacaine0.691
13Carvedilol0.691
14Dibucaine0.691
15Domperidone0.691
16Nisoldipine0.691
17Nitrendipine0.691
18Ropivacaine0.691
19Veratridine0.691

About SCN5A as a Drug Target

SCN5A (sodium voltage-gated channel alpha subunit 5) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 19 compounds with documented SCN5A interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

SCN5A inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.